Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Clinical trial NCT03630120 · TERMINATED

Trial details

NCT number: NCT03630120
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Thyroid Cancer Thyroid Cancer, Medullary Differentiated Thyroid Cancer Papillary Thyroid Cancer Follicular Thyroid Cancer Poorly Differentiated Thyroid Gland Carcinoma

Start date: 2018-08-06
Primary completion: 2019-11-14
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.